Home > Dermatology > SPIN 2019 > Reduction in coronary artery disease in psoriasis patients treated with biologic therapies

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies

Treating psoriasis with biologic drugs that target the immune system can reduce early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke. The association between psoriasis and occlusive cardiovascular events was noted originally nearly 50 years ago [1], and it is generally attributed to the heightened systematic inflammation present in psoriasis patients, which results in excess low-density lipoproteins lining the arteries. What was not yet known was whether modulating the inflammatory condition with immunotherapy would result in reduced risk of cardiovascular disease.

Dr Nehal Mehta (National Heart, Lung, and Blood Institute, NIH, USA) presented the just-published results of the first in-human evidence that treating psoriasis patients with biologic systemic therapies has positive consequences on cardiovascular outcomes [2]. This prospective, observational study of the NIH Psoriasis Atherosclerosis Cardiometabol...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on